By Fineline Cube Hansoh Pharmaceutical (HKG: 3692) announced that the marketing authorization application for its independently developed HS‑20093 (Risvutatug Rezetecan) for injection has been accepted by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with small cell lung cancer (SCLC) who have failed prior platinum‑based therapy (acceptance number: CXSS2600134). The filing is underpinned by the pivotal ARTEMIS‑008 Phase III trial, which in July 2026 became the first global Phase III study to demonstrate a significant overall survival benefit with a B7‑H3‑targeted antibody‑drug conjugate (ADC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Application Type | Marketing authorization application (accepted) |
| Acceptance No. | CXSS2600134 |
| Product | HS‑20093 (Risvutatug Rezetecan) for injection |
| Indication | Adult SCLC patients who have failed prior platinum‑based therapy |
| Date | Sept 3, 2026 |
Drug Profile & Mechanism of Action
- Molecule: HS‑20093 (Risvutatug Rezetecan), an independently developed antibody‑drug conjugate (ADC) from Hansoh Pharmaceutical
- Target: B7‑H3, an immune‑checkpoint‑related antigen broadly overexpressed in SCLC and other solid tumors
- Innovation: First B7‑H3‑targeted ADC worldwide to demonstrate a significant overall survival benefit in a global Phase III trial
- Registration Basis: Pivotal Phase III ARTEMIS‑008 study (Trial No.: ARTEMIS‑008) in SCLC patients who progressed or relapsed after platinum‑based therapy
Clinical Evidence – ARTEMIS‑008
| Item | Detail |
|---|---|
| Trial | ARTEMIS‑008, pivotal Phase III |
| Population | SCLC patients with progression or relapse after platinum‑based therapy |
| Primary Endpoint | Overall survival (OS) |
| Result | Primary endpoint met (July 2026) |
| Significance | First global Phase III trial to show significant OS benefit with a B7‑H3 ADC |
The OS result represents a positive breakthrough for the B7‑H3 ADC field and for second‑line SCLC, one of the most treatment‑resistant thoracic malignancies, where survival gains beyond chemotherapy have historically been difficult to achieve.
Market Impact & Outlook
- First‑mover evidence: As the first global Phase III OS win for any B7‑H3 ADC, HS‑20093 establishes the strongest clinical benchmark in its target class to date
- Large unmet need: Second‑line SCLC carries a poor prognosis and limited standard‑of‑care options, positioning HS‑20093 for significant potential uptake if approved
- Regulatory momentum: NMPA acceptance of the NDA moves Hansoh Pharmaceutical one step closer to a potential first‑in‑class domestic launch in this indication
- Pipeline signal: The result validates Hansoh’s internal ADC discovery engine and strengthens its competitive standing in the rapidly expanding ADC landscape
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the regulatory review timeline, approval prospects, and commercial potential of HS‑20093 in SCLC. Actual results may differ materially due to regulatory, clinical, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech